Free circulating mRNA in plasma from breast cancer patients and clinical outcome.

[1]  M. Provencio,et al.  Extracellular tumor DNA in plasma and overall survival in breast cancer patients , 2006, Genes, chromosomes & cancer.

[2]  M. Provencio,et al.  Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential , 2006, Clinical Cancer Research.

[3]  T. Aoki,et al.  Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy. , 2005, International journal of molecular medicine.

[4]  Robert L Sutherland,et al.  Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. , 2005, Endocrine-related cancer.

[5]  K. Danenberg,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. , 2005, Cancer letters.

[6]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[7]  Y. Lo,et al.  Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jose M. Silva,et al.  RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma , 2002, Genes, chromosomes & cancer.

[11]  D. Sargent,et al.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Blomgren,et al.  Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Provencio,et al.  Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells , 2002, Gut.

[14]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Provencio,et al.  Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Jose M. Silva,et al.  Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations , 2001, Genes, chromosomes & cancer.

[17]  J. Garcia-conde,et al.  Real-Time Quantification in Plasma of Human Telomerase Reverse Transcriptase (hTERT) mRNA: A Simple Blood Test to Monitor Disease in Cancer Patients , 2001, Laboratory Investigation.

[18]  J. Foekens,et al.  Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. , 2001, Cancer research.

[19]  R. Blamey,et al.  Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  C. Allegra.  Antifolates: the next millennium. , 1999, Seminars in oncology.

[21]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[24]  H. Lovec,et al.  Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice. , 1994, The EMBO journal.

[25]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[26]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[28]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[29]  D. Santi,et al.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. , 1974, Biochemistry.